Sector revisions Genmab A/S Nasdaq

Stocks

Market Closed - Nasdaq 21:00:00 13/08/2026 BST			5-day change	1st Jan Change
31.34 ^USD	-0.25%		+5.06%	+1.75%

08-12	BNP Paribas Initiates Genmab at Outperform, With $40 Price Target	MT
08-12	Nordic stocks in North America: AstraZeneca fell 1.0%	FW

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	WUXI APPTEC CO., LTD.							18
	ARGENX SE							15
	INSMED INCORPORATED							22
	WUXI BIOLOGICS (CAYMAN) INC.							23
	BIONTECH SE							20
	PHARMAESSENTIA CORPORATION							7
	GENMAB A/S							15
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.							18
	EXELIXIS, INC.							16
	ARROWHEAD PHARMACEUTICALS, INC.							11
	MADRIGAL PHARMACEUTICALS, INC.							16
	SUMMIT THERAPEUTICS INC.							13
	AKESO, INC.							21
	CYTOKINETICS, INCORPORATED							20
	REMEGEN CO., LTD.							16
	CRINETICS PHARMACEUTICALS, INC.							10
	VAXCYTE, INC.							9
	IMMUNITYBIO, INC.							4
	Average							15
	Weighted average by Cap.							16